Application of deferoxamine mesylate in preparation of antitumor drugs

A technology of deferoxamine mesylate and anti-tumor drug, applied in the field of anti-tumor drugs, can solve the problem of no report of deferoxamine mesylate, and achieve the effects of reducing iron load, inhibiting growth, and inhibiting HCC proliferation

Pending Publication Date: 2021-10-01
XINXIANG MEDICAL UNIV
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no report on the research of defer...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of deferoxamine mesylate in preparation of antitumor drugs
  • Application of deferoxamine mesylate in preparation of antitumor drugs
  • Application of deferoxamine mesylate in preparation of antitumor drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1 CCK-8 method to detect the effect of DFO on the proliferation of liver cancer cells

[0033] HepG2, Huh7 and Hepa1-6 cells were treated with different concentrations of DFO (0, 25, 50, 100mol / L). cells in 3×10 per well 3 Cells were seeded in 96-well plates. Some cells were incubated with different concentrations of DFO (25, 50, 100 mol / L, DFO was purchased from Novartis Pharmaceutical Co., Ltd.), and other cells were used as the control group. After culturing for 12 hours, 10 mol / L of CCK-8 (Dojindo, Kumamoto Island, Japan) cells were added to each well at designated time points (24, 48, 72 and 96 hours). After the cells were incubated for 2 hours, the optical density was measured at 450 nm with a microplate reader.

[0034]The result is as figure 1 As shown in A-C, the cell proliferation of 25, 50, 100mol / L DFO groups was significantly different from that of the control group. Therefore, we chose DFO with a dose of 25mol / L for 48h further experiment.

Embodiment 2

[0035] Example 2 RTCA real-time cell analysis system dynamically monitors the effect of DFO on the proliferation of liver cancer cells

[0036] The growth rate of HCC cells was measured by RTCA real-time label-free cell function analyzer (IXL8, ACEA, USA). Place the RTCA real-time label-free cell function analyzer at 37°C, 5% CO 2 In a humidified incubator, add 100ul / well medium containing 10% FBS to an 8-well electronic plate, and immediately record the background reading. Then 48,000 liver cancer cells were added to 300 rat liver cell suspensions. After incubation for 24 hours, DFO was added to the medium (the final concentration of DFO was 25 mol / L), and the cell growth rate was recorded every 1 hour for continuous monitoring for 96 hours.

[0037] The results showed that 25mol / L DFO treatment significantly inhibited the proliferation of HepG2, Huh7 and Hepa1-6 cells ( figure 1 D-F).

Embodiment 3

[0038] Example 3 Clonogenic test

[0039] HepG2, Huh7 and Hepa1-6 cells were seeded in 6-well plates (500 cells / well), and the experimental group was treated with 25mol / L DFO. Cells were incubated at 37°C for 10 days. On the 10th day, the cells were washed 3 times with PBS. Fix with 4% paraformaldehyde for 30 min, stain with 0.5% crystal violet for 30 min at room temperature, observe and count cell colonies.

[0040] The results of the colony formation experiment showed that compared with the control group, the proliferation ability of the cells treated with 25mol / L DFO decreased significantly. Compared with the control group, the colony formation rates of HepG2, Huh7 and Hepa1-6 cells decreased by 52.74%, 52.13% and 89.07% after DFO treatment (Pfigure 1 G, H).

[0041] From the test results of Examples 1-3, it can be seen that DFO can inhibit the proliferation of liver cancer cells in vitro.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of deferoxamine mesylate in preparation of antitumor drugs. In-vitro experiments prove that the deferoxamine mesylate (DFO) can inhibit proliferation of liver cancer cells in vitro; and a mouse-borne tumor test proves that 100 mg/kg of the DFO is a safe dosage for mice, and the growth of xenotransplantation tumors can be inhibited with the dosage. In-vivo and in-vitro test results are consistent to show that the DFO can reduce iron load of hepatoma carcinoma cells and inhibit proliferation of hepatoma carcinoma cells, and has an anti-tumor effect. The anti-tumor action mechanism of the DFO is further studied, and it is found that the DFO reduces the iron content of cells, mitochondrial dysfunction is caused by destroying a mitochondrial structure and a mitochondrial respiration electron transport chain, so cell energy metabolism is affected, and liver cancer cell proliferation is inhibited; and meanwhile, the DFO can retard the progress of a tumor cell cycle, so HCC proliferation and tumor growth are inhibited. The invention provides the novel medical application of deferoxamine mesylate.

Description

technical field [0001] The invention belongs to the technical field of antineoplastic drugs, and in particular relates to the application of deferoxamine mesylate in the preparation of antineoplastic drugs. Background technique [0002] Hepatocellular carcinoma (HCC) accounts for more than 90% of primary liver cancers and is the most common malignant tumor of the digestive tract. Statistics from the WHO International Cancer Center show that there are more than 700,000 new cases of HCC every year in the world, which is the second leading cause of cancer death in the world, and my country is the hardest hit area of ​​HCC, with more than 50% of the world's incidence and death. HCC is rich in blood supply, occurs in multiple centers, is aggressive, prone to intrahepatic spread and extrahepatic metastasis, and has a poor prognosis. Once discovered, it is already in the middle and late stages, with only 15% operable rate and 12.1% overall survival rate. The traditional treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/16A61P35/00A61P1/16
CPCA61K31/16A61P35/00A61P1/16
Inventor 任峰李健吴凯旋杨莹莹史应豪
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap